US009511077B2

(12) **United States Patent**
Biggs et al.

(10) **Patent No.: US 9,511,077 B2**
(45) **Date of Patent: *Dec. 6, 2016**

(54) **MEDICAL DEVICES AND METHODS COMPRISING AN ANABOLIC AGENT FOR WOUND HEALING**

(75) Inventors: **Danielle L. Biggs**, Collierville, TN (US); **Jared T. Wilsey**, Memphis, TN (US)

(73) Assignee: **Warsaw Orthopedic, Inc.**, Warsaw, IN (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 591 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/093,479**

(22) Filed: **Apr. 25, 2011**

(65) **Prior Publication Data**

US 2012/0271275 A1 Oct. 25, 2012

(51) **Int. Cl.**

A61M 31/00	(2006.01)
A61K 31/58	(2006.01)
A61K 38/27	(2006.01)
A61K 38/28	(2006.01)
A61K 38/30	(2006.01)
A61L 26/00	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 31/58*** (2013.01); ***A61K 38/27*** (2013.01); ***A61K 38/28*** (2013.01); ***A61K 38/30*** (2013.01); ***A61L 26/009*** (2013.01); ***A61L 26/0066*** (2013.01); *A61L 2300/222* (2013.01); *A61L 2300/414* (2013.01); *A61L 2300/43* (2013.01); *A61L 2300/604* (2013.01)

(58) **Field of Classification Search**

CPC A61K 31/58; A61K 38/27; A61K 38/28; A61K 38/30; A61L 2300/222; A61L 2300/414; A61L 2300/43; A61L 2300/604; A61L 26/0066; A61L 26/009

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,624,255	A	11/1986	Schenck et al.
4,742,054	A	5/1988	Naftchi
4,863,457	A	9/1989	Lee
5,522,844	A	6/1996	Johnson
5,571,882	A	11/1996	Vetter
5,626,838	A	5/1997	Cavanaugh, Jr.
5,707,647	A	1/1998	Dunn et al.
5,759,583	A	6/1998	Iwamoto et al.
5,868,789	A	2/1999	Huebner
5,942,241	A	8/1999	Chasin et al.
6,069,129	A	5/2000	Sandberg et al.
6,179,862	B1	1/2001	Sawhney
6,248,345	B1	6/2001	Goldenheim et al.
6,287,588	B1	9/2001	Shih et al.
6,326,020	B1	12/2001	Kohane et al.
6,331,311	B1	12/2001	Brodbeck et al.
6,428,804	B1	8/2002	Suzuki et al.
6,461,631	B1	10/2002	Dunn et al.
6,524,607	B1	2/2003	Goldenheim et al.
6,534,081	B2	3/2003	Goldenheim et al.
6,589,549	B2	7/2003	Shih et al.
6,616,946	B1	9/2003	Meier et al.
6,630,155	B1	10/2003	Chandrashekar et al.
6,632,457	B1	10/2003	Sawhney
6,652,883	B2	11/2003	Goupil et al.
6,676,971	B2	1/2004	Goupil et al.
6,710,126	B1	3/2004	Hirt et al.
6,723,741	B2	4/2004	Jeon et al.
6,723,814	B2	4/2004	Meier et al.
6,756,058	B2	6/2004	Brubaker et al.
6,773,714	B2	8/2004	Dunn et al.
6,921,541	B2	7/2005	Chasin et al.
6,974,462	B2	12/2005	Sater
7,070,809	B2	7/2006	Goupil et al.
7,144,412	B2	12/2006	Wolfe et al.
7,166,570	B2	1/2007	Hunter et al.
7,220,281	B2	5/2007	Lambrecht et al.
7,229,441	B2	6/2007	Trieu et al.
7,235,043	B2	6/2007	Gellman et al.
7,287,983	B2	10/2007	Ilan
7,318,840	B2	1/2008	McKay
7,329,259	B2	2/2008	Cragg
7,361,168	B2	4/2008	Makower et al.
7,367,978	B2	5/2008	Drewry et al.
7,829,110	B2	11/2010	Wohlert
8,470,360	B2 *	6/2013	McKay 424/426

(Continued)

FOREIGN PATENT DOCUMENTS

WO	03005961	A2	1/2003
WO	2005034998	A2	4/2005
WO	2007005177	A1	1/2007

OTHER PUBLICATIONS

Chhipa et al "Formulation Optimization of Sustained Release Pellets of Itopride Hydrochloride using Different Polymers," Journal of Pharmacy Research 2009 2(8) 1404-1408).*

International Search Report and Written Opinion for PCT/US2012/027464, the counterpart application mailed on Sep. 19, 2012.

American Burn Association, Burn Incidence and Treatment in the United States: 2011 Fact Sheet, 1 pg.

QLT, Inc., Atrigel, Drug Delivery Platform, www.qltinc.com, Fort Collins, CO, U.S., Jul. 2006, 2 pgs.

Lynda Cole, RN and Caroline Nesbitt, RN, A Three-Year Multiphase Pressure Ulcer Prevalence/Incidence Study in a Regional Referral Hospital, vol. 57, Issue 1, Jan. 2011, pp. 1-5.

(Continued)

Primary Examiner — Suzanne Ziska

(74) *Attorney, Agent, or Firm* — Sorell Lenna & Schmidt LLP

(57) **ABSTRACT**

Improved medical devices and methods are provided comprising an anabolic agent for wound healing. These improved medical devices and methods can enhance wound healing in wounds from cuts, abrasions, lesions, burns including sunburn, surgical incisions, pressure ulcers, diabetic ulcers, traumatic wounds, or other injuries or maladies, which can be chronic or non-chronic in origin. In some embodiments, the medical device comprises a drug depot that releases the anabolic agent over at least 3 days to enhance wound healing.

8 Claims, 1 Drawing Sheet